Interferon beta for secondary progressive multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Rice, George P A ^b   Ebers, George ^c   Fredrikson, Sten ^d   Tesser, Fabiana ^e   Filippini, Graziella ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT BETA INTERFERON; RECOMBINANT BETA INTERFERON 1A; RECOMBINANT BETA INTERFERON 1B; UNCLASSIFIED DRUG;

CLINICAL EVALUATION; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DATA ANALYSIS; DATA EXTRACTION; DISEASE COURSE; DRUG EFFECT; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INCIDENCE; INFORMATION PROCESSING; INTERVENTION STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; QUALITY CONTROL; QUALITY OF LIFE; RELAPSE; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 70249114035     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005181.pub2     Document Type: Review

References (17)

1. Alderson P, Green S, Higgins JPT, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.2 [updated December 2003]. The Cochrane Library. Chichester, UK:: John Wiley & Sons, Ltd, 2004, issue 1.
2. Benedict RH, Fischer JS, Archibald CJ, Arnett PA, Beatty WW, Bobholz J, et al.Minimal neuropsychological assessment of MS patients: a consensus approach. Clinical Neuropsychology 2002;16(3):381-397 [MEDLINE: 12607150] (Pubitemid 36390381)
3. Compston A, Coles A. Multiple Sclerosis. Lancet 2002;359(9313): 1221-1231 [MEDLINE: 11955556]
4. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. New England Journal of Medicine 2000;343(20):1430-1438 (Pubitemid 30832878)
5. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-188
6. Ebers GC, Koopman WJ, Hader W, Sadovnick AD, Kremenchutzky M, Mandalfino P, et al.The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis. Brain 2000;123(Pt 3):641-649 (Pubitemid 30099546)
7. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. British Medical Journal 1997;315(7109):629-634 (Pubitemid 27387172)
8. Filippini, Munari L, Ebers GC, D'Amico R, Rice GPA. Interferons in relapsing remitting multiple sclerosis. The Lancet 2003;361(9371): 545-552
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414): 557-560
10. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11): 1444-1452 [MEDLINE: 84040263]
11. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46(4):907-911
12. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al.Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001;50(1):121-127 [MEDLINE: 11456302]
13. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. New England Journal of Medicine 2000;343(13): 938-952
14. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al.New diagnostic criteria formultiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13(3):227-231 [MEDLINE: 83202737] (Pubitemid 13158528)
15. Rice G PA, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al.Interferon in relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: Art. No.: CD002002]
16. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116(Pt 1):117-134 (Pubitemid 23087038)
17. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al.The natural history of multiple sclerosis:a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112(Pt 6):1419-28. * Indicates the major publication for the study (Pubitemid 20024212)